Sun On Course To Launch Safinamide For Parkinson’s In India
Safinamide appears to be headed for a debut on the Indian market, after Sun Pharma received a go-ahead from a key expert panel for the Parkinson’s disease treatment. Pricing of the selective monoamine oxidase B inhibitor and innovator Newron’s stance around the emerging India activity for the product could be interesting to watch.
You may also be interested in...
Sun has promised to implement certain changes to address corporate governance concerns that have riled investors, including “unwinding” a loan transaction and doing away with a controversial related party arrangement for domestic sales. But will that be enough for markets to "forget" allegations of lapses or "re-rate" the firm any time soon?
Newron has raised $27m via a private placement to fund late-stage development of its novel schizophrenia drug and to license new assets that will bulk up its limited clinical pipeline.
First new chemical entity for Parkinson's to clear FDA in 10 years, Xadago has a narrower indication than Teva's Azilect and similar pricing.